Aernoud T.L. Fiolet, MD1,2; Stefan M. Nidorf, MD, MBBS, FRACP3; Arend Mosterd, MD, PhD, FESC2,4; and Jan H. Cornel, MD, PhD, FESC5

1 Department of Cardiology, University Medical Centre Utrecht, Utrecht, the Netherlands; 2 Dutch Network for Cardiovascular Research (WCN), Utrecht, the Netherlands; 3 Heart Care Western Australia, Perth, Western Australia, Australia; 4 Department of Cardiology, Meander Medisch Centrum, Amersfoort, the Netherlands; and 5 Department of Cardiology, Northwest Clinics, Alkmaar, the Netherlands

  1. Roth, G.A., Huffman, M.D., Moran, A.E. et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015; 132: 1667−1678
  2. World Health Organization (WHO). Top 10 causes of death worldwide.; 2017 Date accessed: October 17, 2017
  3. Abubakar II, Tillmann, T., and Banerjee, A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990−2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117−171
  4. Sidney, S., Quesenberry, C.P.J., Jaffe, M.G. et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. 2016; 1: 594−599
  5. Ezzati, M., Obermeyer, Z., Tzoulaki, I., Mayosi, B.M., Elliott, P., and Leon, D.A. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol. 2015; 12: 508−530
  6. Vidal-Petiot, E., Ford, I., Greenlaw, N. et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016; 388: 2142−2152
  7. Montalescot, G., Sechtem, U., Achenbach, S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34: 2949−3003
  8. Maddox, T.M., Stanislawski, M.A., Grunwald, G.K. et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014; 312: 1754−1763 681
  9. Sedlak, T.L., Lee, M., Izadnegahdar, M., Merz, C.N.B., Gao, M., and Humphries, K.H. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J. 2013; 166: 38−44
  10. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., and Dagenais, G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145−153
  11. Ridker, P.M. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016; 37: 1720−1722
  12. Libby, P., Ridker, P.M., and Hansson, G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54: 2129−2138
  13. Falk, E. and Shah, P.K. Pathogensis of atherothrombosis. Role of vulnerable, ruptured, and erodod plaques. in: V. Fuster, E.J. Topol, E.G. Nabel (Eds.) Atherothrombosis and coronary artery disease (2). Wolters Kluwer Health, Philadelphia, PA; 2004: 1676
  14. Abela, G.S. and Aziz, K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events—a novel insight into plaque rupture by scanning electron microscopy. Scanning. 2006; 28: 1−10
  15. Abela, G.S., Aziz, K., Vedre, A., Pathak, D.R., Talbott, J.D., and DeJong, J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009; 103: 959−968
  16. Duewell, P., Kono, H., Rayner, K.J. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464: 1357−1361
  17. Mulay, S.R. and Anders, H.J. Crystallopathies. N Engl J Med. 2016; 374: 2465−2476
  18. Rajamäki, K., Lappalainen, J., Öörni, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010; 5: e11765
  19. Hornung, V., Bauernfeind, F., Halle, A. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9: 847−856
  20. Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B.T., and Tschopp, J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008; 320: 674−677 156 995
  21. Triantafilou, M., Hughes, T.R., Morgan, B.P., and Triantafilou, K. Complementing the inflammasome. Immunology. 2016; 147: 152−164 556
  22. Libby, P., Tabas, I., Fredman, G., and Fisher, E.A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014; 114: 1867−1879 699
  23. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237−241
  24. Terkeltaub, R.A., Furst, D.E., Bennett, K., Kook, K.A., Crockett, R.S., and Davis, M.W. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010; 62: 1060−1068
  25. Khanna, D., Khanna, P.P., Fitzgerald, J.D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012; 64: 1447−1461
  26. Ridker, P.M., Everett, B.M., Thuren, T. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377: 1119−1131
  27. Huang, C., Cen, C., Wang, C., Zhan, H., and Ding, X. Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis. 2014; 13: 1
  28. Hollander, W., Paddock, J., Nagraj, S., Colombo, M., and Kirkpatrick, B. Effects of anticalcifying and anti-fibrotic drugs on pre-established atherosclerosis in the rabbit. Atherosclerosis. 1979; 33: 111−123
  29. Kong, J., Deng, Y., Dong, Q., Liu, W., and Lu, Y. Colchicine reduces restenosis after balloon angioplasty treatment for in-stent restenosis. Arch Med Res. 2015; 46: 101−106
  30. Crittenden, D.B., Lehmann, R.A., Schneck, L. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012; 39: 1458−1464 533
  31. Solomon, D.H., Liu, C.C., Kuo, I.H., Zak, A., and Kim, S.C. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016; 75: 1674−1679−207 984
  32. Deftereos, S., Giannopoulos, G., Kossyvakis, C. et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012; 60: 1790−1796
  33. Deftereos, S., Giannopoulos, G., Panagopoulou, V. et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014; 2: 131−137
  34. Nidorf, M. and Thompson, P.L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007; 99: 805−807
  35. Nidorf, S.M., Eikelboom, J.W., Budgeon, C.A., and Thompson, P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61: 404−410
  36. O’Keefe, J.H., McCallister, B.D., Bateman, T.M., Kuhnlein, D.L., Ligon, R.W., and Hartzler, G.O. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992; 19: 1597−1600
  37. Deftereos, S., Giannopoulos, G., Angelidis, C. et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015; 132: 1395−1403 611
  38. Muller, D.W.M., Ellis, S.G., and Topol, E.J. Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 1991; 17: 126−131
  39. Colchicine cardiovascular outcomes trial (COLCOT). (NCT02551094); 2015 Date accessed: October 17, 2017
  40. Imazio COACS colchicine for acute coronary syndromes. (NCT01906749); 2013 Date accessed: October 17, 2017
  41. ANZCTR. The LoDoCo2 Trial: low dose colchicine for secondary prevention of cardiovascular disease. (ACTRN12614000093684); 2014 771 Date accessed: September 30, 2017
  42. Colchicine and spironolactone in patients with STEMI/SYNERGY stent Registry (CLEAR-SYNERGY) NCT03048825.; 2017 Date accessed: October 17, 2017
  43. Colchicine for prevention of vascular inflammation in non-cardio embolic stroke (CONVINCE). (NCT02898610); 2016 Date accessed: October 17, 2017
  44. Hemkens, L.G., Gloy, V.L., Olu, K.K., Nordmann, A.J., and Briel, M. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2014; 3: CD011047
  45. Verma, S., Eikelboom, J.W., Nidorf, S.M. et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015; 15: 1
  46. Niel, E. and Scherrmann, J.M. Colchicine today. Jt Bone Spine. 2006; 73: 672−678
  47. Zemer, D., Revach, M., Pras, M. et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med. 1974; 291: 932−934
  48. Zemer, D., Livneh, A., Danon, Y.L., Pras, M., and Sohar, E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991; 34: 973−977
  49. Banach, M., Rizzo, M., Toth, P.P. et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci AMS. 2015; 11: 1
  50. Tournoij, E., Peters, R.J.G., Langenberg, M., Kanhai, K.J.K., and Moll, F.L. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg. 2009; 37: 597−603
  51. Hull, K. FDA medical review. Colchicine for the treatment of FMF.; 2008 2352s000_MedR.pdf
  52. Wilbur, K. and Makowsky, M. Colchicine myotoxicity: case reports and literature review. Pharmacother J Hum Pharmacol Drug Ther. 2004; 24: 1784−1792
  53. Tufan, A., Dede, D.S., Cavus, S., Altintas, N.D., Iskit, A.B., and Topeli, A. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. (aph.1H064 [pii])Ann Pharmacother. 2006; 40: 1466−1469
  54. Wallace, S.L., Singer, J.Z., Duncan, G.J., Wigley, F.M., and Kuncl, R.W. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991; 18: 264−269
  55. Leighton, J.A., Bay, M.K., Maldonado, A.L., Schenker, S., and Speeg, K.V. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology. 1991; 14: 1013−1015
  56. Ben Chetrit, E. and Levy, M. Colchicine. 1998 Update. Semin Arthritis Rheum. 1998; 28: 48−59
  57. Akdag, I., Ersoy, A., Kahvecioglu, S., Gullulu, M., and Dilek, K. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol. 2006; 19: 515
  58. Caraco, Y., Putterman, C., Rahamimov, R., and Ben-Chetrit, E. Acute colchicine intoxication—possible role of erythromycin administration. J Rheumatol. 1992; 19: 494−496
  59. Hung, I.F., Wu, A.K., Cheng, V.C. et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. (CID36109 [pii])Clin Infect Dis. 2005; 41: 291−300
  60. Schenone, A.L. and Menon, V. Colchicine in pericardial disease: from the underlying biology and clinical benefits to the drug-drug interactions in cardiovascular medicine. Curr Cardiol Rep. 2018; 20: 62
  61. Ayubi, E. and Safiri, S. Risk of colchicine-associated myopathy in gout: influence of concomitant use of statin; methodologic issues. Am J Med. 2017; 130: e467
  62. Wason, S., Digiacinto, J.L., and Davis, M.W. Clinically significant pharmacokinetic interaction between colchicine and ritonavir in healthy volunteers. Clin Med Insights Therapeutics. 2013; 5: 25
  63. Frydrychowicz, C., Pasieka, B., Pierer, M., Mueller, W., Petros, S., and Weidhase, L. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report. J Med Case Rep. 2017; 11: 8
  64. Wiggins, B.S., Saseen, J.J., Page, R.L. et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016; 134: e468-e495
  65. Baker, S.K., Goodwin, S., Sur, M., and Tarnopolsky, M.A. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004; 30: 799−802
  66. Alayli, G., Cengiz, K., Canturk, F., Durmus, D., Akyol, Y., and Menekse, E.B. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. (aph.1E593 [pii])Ann Pharmacother. 2005; 39: 1358−1361
  67. Terkeltaub, R.A., Furst, D.E., DiGiacinto, J.L., Kook, K.A., and Davis, M.W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011; 63: 2226−2237
  68. Minetti, E.E. and Minetti, L. Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine. J Nephrol. 2003; 16: 421−426

(Clin Ther. 2019;41: 30−40) © 2018 Опубликовано Elsevier Inc.